Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4826
Rani Therapeutics
RANI
$93.6M
| $10.9K | ﹤0.01% |
+8,096
| New | +$12.2K |
2025 Q4
0 quarters
|
|
4827
Sensus Healthcare
SRTS
$49.1M
| $10.9K | ﹤0.01% |
2,738
| – | – |
2024 Q4
4 quarters
|
|
4828
VanEck Natural Resources ETF
HAP
$332M
| $10.8K | ﹤0.01% |
+180
| New | +$10.6K |
2025 Q4
0 quarters
|
|
4829
FT Vest US Equity Buffer ETF November
FNOV
$1.26B
| $10.8K | ﹤0.01% |
197
-3,537
| -95% | -$190K |
2025 Q1
3 quarters
|
|
|
CCCX
4830
DELISTED
Churchill Capital Corp X
CCCX
| $10.7K | ﹤0.01% |
687
-34,054
| -98% | -$573K |
2025 Q3
1 quarter
|
|
4831
American Resources Corp
AREC
$191M
| $10.5K | ﹤0.01% |
+4,226
| New | +$14.1K |
2025 Q4
0 quarters
|
|
4832
Vanguard Extended Market ETF
VXF
$30.6B
| $10.5K | ﹤0.01% |
+50
| New | +$10.5K |
2025 Q4
0 quarters
|
|
|
EXK
4833
Endeavour Silver
EXK
$2.55B
| $10.3K | ﹤0.01% |
1,093
-54
| -5% | -$458 |
2024 Q2
6 quarters
|
|
|
VLOSU
4834
Velos Acquisition I Corp Units
VLOSU
$278M
| $10.3K | ﹤0.01% |
1,005
| – | – |
2024 Q4
4 quarters
|
|
4835
First Trust Global Wind Energy ETF
FAN
$200M
| $10.2K | ﹤0.01% |
+500
| New | +$10.1K |
2025 Q4
0 quarters
|
|
4836
ARK Autonomous Technology & Robotics ETF
ARKQ
$2.08B
| $10.2K | ﹤0.01% |
+89
| New | +$10.3K |
2025 Q4
0 quarters
|
|
|
RPGL
4837
Republic Power Group Ltd
RPGL
$37.5M
| $9.8K | ﹤0.01% |
+1
| New | +$13.4K |
2025 Q4
0 quarters
|
|
4838
Greenfire Resources
GFR
$1.39B
| $9.41K | ﹤0.01% |
+1,976
| New | +$9.39K |
2025 Q4
0 quarters
|
|
4839
iShares Global Infrastructure ETF
IGF
$10.1B
| $9.08K | ﹤0.01% |
+148
| New | +$9.13K |
2025 Q4
0 quarters
|
|
|
PRT
4840
PermRock Royalty Trust Unit
PRT
$22.9M
| $8.99K | ﹤0.01% |
3,221
| – | – |
2024 Q1
7 quarters
|
|
4841
VanEck Indonesia Index ETF
IDX
$34.5M
| $8.91K | ﹤0.01% |
+540
| New | +$8.98K |
2025 Q4
0 quarters
|
|
|
AXG
4842
Solowin Holdings
AXG
$22.4M
| $8.83K | ﹤0.01% |
+2,148
| New | +$7.68K |
2025 Q4
0 quarters
|
|
4843
1stdibs.com
DIBS
$135M
| $8.81K | ﹤0.01% |
1,471
-114
| -7% | -$513 |
2024 Q2
6 quarters
|
|
4844
AllianceBernstein
AB
$3.26B
| $8.73K | ﹤0.01% |
+227
| New | +$9K |
2025 Q4
0 quarters
|
|
|
ADUR
4845
Aduro Clean Technologies
ADUR
$438M
| $8.73K | ﹤0.01% |
843
| – | – |
2024 Q4
4 quarters
|
|
4846
Woori Financial
WF
$18.5B
| $8.53K | ﹤0.01% |
+145
| New | +$8.08K |
2025 Q4
0 quarters
|
|
4847
AC Immune
ACIU
$271M
| $8.48K | ﹤0.01% |
2,701
-2,589
| -49% | -$8.17K |
2024 Q3
5 quarters
|
|
4848
Werewolf Therapeutics
HOWL
$45.1M
| $8.39K | ﹤0.01% |
13,236
-39
| -0.3% | -$47 |
2024 Q1
7 quarters
|
|
|
VG
4849
Venture Global Inc
VG
$32.8B
| $8.37K | ﹤0.01% |
1,227
-28,041
| -96% | -$234K |
2025 Q2
2 quarters
|
|
4850
Global Partners
GLP
$1.59B
| $8.24K | ﹤0.01% |
+197
| New | +$8.67K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.